Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic Lateral Sclerosis

Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig's disease, is a progressive neurodegenerative condition that impacts the nerve cells in the brain and spinal cord. It leads to muscle weakness, paralysis, and eventually respiratory failure. Although the precise cause remains unknown, a combination of genetic and environmental factors is believed to play a role. Diagnosis is made through neurological evaluations and tests to rule out other conditions. While there is no cure for ALS at present, treatments focus on symptom management and enhancing the quality of life. Ongoing research is dedicated to discovering potential therapies and gaining a deeper understanding of the disease.

Simplified, visualized, and ready for you—see the infographic

https://www.delveinsight.com/infographics/amyotrophic-lateral-sclerosis-als-market?utm_source=infographics&utm_medium=promotion&utm_campaign=akpr

Amyotrophic Lateral Sclerosis Epidemiological Segmentation
The Epidemiological Segmentation of ALS across the 7MM from 2020 to 2034 includes:

• Total prevalent population of ALS
  
  

• Diagnosed prevalence of ALS
  
  

• Type-specific distribution of ALS
  
  

• Gender-specific distribution of ALS
  
  

• Mutation-specific distribution of ALS
  
  

• Distribution by site of onset of ALS
  
  

• Age-specific distribution of ALS
  
  

ALS Epidemiology
The total number of diagnosed prevalent ALS cases in the 7MM is approximately 60,000.
In the United States, there are around 26,000 diagnosed ALS cases.
Among these, 15,000 diagnosed cases are in males, while 11,000 are in females.

Break down the numbers. Understand the strategy. Download the report : Click Here

ALS Market
In 2023, the ALS market size in the 7MM was approximately USD 1 billion.

ALS Market Drivers

• Pridopidine, an emerging treatment, is delivered as an easy-to-swallow capsule twice a day, providing a convenient route of administration (RoA), which helps improve patient adherence to treatment plans.
  
  

ALS Market Barriers

• A major challenge in ALS treatment is that current and emerging therapies cannot offer a complete cure, limiting their overall effectiveness and long-term outcomes for patients.
  
  

One graphic, all the essentials— Click to explore

Emerging ALS Drugs

• Masitinib
  
  

• NurOwn
  
  

• ABBV-CLS-7262
  
  

• RAPA 501
  
  

• And others.
  
  

Key Players in ALS Treatment

• Ab Science
  
  

• Alector
  
  

• GSK
  
  

• Brainstorm Cell Therapeutics
  
  

• Ionis Pharmaceuticals
  
  

• Medcinova
  
  

• Denali Therapeutics
  
  

• Abbvie
  
  

• Calico Life Sciences
  
  

• Clene Nanomedicine Biosciences
  
  

• Seelos Therapeutics
  
  

• Prilenia Therapeutics
  
  

• Rapa Therapeutics
  
  

• Neurosense Therapeutics
  
  

• Helixmith
  
  

• Transposon Therapeutics
  
  

• Revalesio Corporation
  
  

• Annexon Biosciences
  
  

• Corcept Therapeutics
  
  

• Al-S Pharma
  
  

• Sanofi
  
  

• Denali Therapeutics
  
  

• Orphai Therapeutics
  
  

• And others.
  
  

From snapshot to strategy—unlock the full report

https://www.delveinsight.com/report-store/amyotrophic-lateral-sclerosis-als-market?utm_source=infographics&utm_medium=promotion&utm_campaign=akpr